New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Cardio Diagnostics Holdings, Inc. (CDIO) vs Heatwurx Inc. (PCSA)

Cardio Diagnostics Holdings, Inc. and Heatwurx Inc. are both Biotechnology companies. Cardio Diagnostics Holdings, Inc. and Heatwurx Inc. are of similar size ($4.9M and $4.8M). Cardio Diagnostics Holdings, Inc. grew revenue faster over the last twelve months: −3.16% against −34.5%. Heatwurx Inc. has the higher net margin (0.00% vs −42,401.3%) and the higher return on invested capital (0.00% vs −228.0%). Across the 15 metrics below, Heatwurx Inc. leads on 10 and Cardio Diagnostics Holdings, Inc. on 5.

Valuation

Metric CDIO PCSA Biotechnology median
P/E n/m n/m 8.26
P/S 319.11 37.91 9.20
P/B 0.85 n/m 2.09
Price to free cash flow n/m n/m 24.49
EV/EBITDA n/m 0.90 0.67
EV/Sales 61.40 (1,326.40) 9.05
Earnings yield (153.33%) (3,520.03%) (34.24%)
Free cash flow yield (118.47%) (298.72%) (24.77%)

Profitability

Metric CDIO PCSA Biotechnology median
Gross margin 100.00% 0.00% 70.18%
Operating margin (42,328.76%) 0.00% 0.00%
Net margin (42,401.31%) 0.00% 0.00%
Free cash flow margin (37,804.58%) 0.00% 0.00%
Return on equity (93.55%) 220.06% (51.58%)
Return on assets (87.24%) (203.76%) (45.91%)
Return on invested capital (227.99%) 0.00% 0.00%

Growth

Metric CDIO PCSA Biotechnology median
Revenue growth (TTM) (3.16%) (34.50%) 7.20%
EPS growth (last fiscal year) 60.15% 89.29% 29.04%
Revenue growth, 5-year CAGR — — 9.48%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric CDIO PCSA Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 17.44 97.70 4.83
Net debt to EBITDA 0.84 0.40 1.01

Dividend

Metric CDIO PCSA Biotechnology median
Dividend yield — — 0.40%
Payout ratio — — —

Size

Metric CDIO PCSA Biotechnology median
Market cap 4.88m 4.76m 155.23m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack